Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease
Open Access
- 15 March 2013
- journal article
- other
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 12 (4), 324
- https://doi.org/10.1038/nrd3842-c1
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Sting of Alzheimer's failures offset by upcoming prevention trialsNature Reviews Drug Discovery, 2012
- Down's syndrome and Alzheimer's disease: towards secondary preventionNature Reviews Drug Discovery, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive declineNature, 2012
- Testing the Right Target and Right Drug at the Right StageScience Translational Medicine, 2011
- Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of agingNeurobiology of Aging, 2010
- Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectivesNature Reviews Drug Discovery, 2010
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002